Dainippon Buys Boston Biomedical To Build On Cancer Strategy
This article was originally published in PharmAsia News
Executive Summary
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.
You may also be interested in...
Dainippon Sumitomo Rolls Out Latuda; Will Sepracor's $2.6 Billion Sales Force Pay Off?
TOKYO - Dainippon Sumitomo launched its atypical antipsychotic Latuda (lurasidone) in the U.S. Feb. 4, and now the pressure is on to capitalize on the sales force it acquired in the acquisition of Sepracor. Analysts' eyes will be on Latuda's initial sales to gauge the company's acquired ability to market its in-house drugs in the U.S
Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
Buying the Lunesta marketer gives the Japanese pharma an experienced U.S. regulatory and commercial team ahead of lurasidone launch.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.